- Home
- PLTR vs ABBV Comparison
PLTR vs ABBV Comparison
Compare PLTR & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLTR | ABBV |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 428.6B | 451.5B |
| IPO Year | 2020 | 2012 |
Fundamental Metrics
Financial Performance| Metric | PLTR | ABBV |
|---|---|---|
| Price | $160.48 | $290.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 33 | 29 |
| Target Price | $217.97 | ★ $306.42 |
| AVG Volume (30 Days) | ★ 20.3M | 4.0M |
| Earning Date | 11-02-2026 | 10-30-2026 |
| Dividend Yield | N/A | ★ 2.53% |
| EPS Growth | ★ 231.58 | N/A |
| EPS | 1.19 | ★ 4.79 |
| Revenue | $4,475,446,000.00 | ★ $61,160,000,000.00 |
| Revenue This Year | $91.02 | $10.87 |
| Revenue Next Year | $52.07 | $9.00 |
| P/E Ratio | $144.36 | ★ $61.55 |
| Revenue Growth | ★ 56.18 | 8.57 |
| 52 Week Low | $106.37 | $190.75 |
| 52 Week High | $212.94 | $298.74 |
Technical Indicators
Market Signals| Indicator | PLTR | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 32.62 | 59.06 |
| Support Level | $125.17 | $278.01 |
| Resistance Level | $191.53 | $291.40 |
| Average True Range (ATR) | 9.14 | 7.63 |
| MACD | -4.98 | -0.47 |
| Stochastic Oscillator | 16.98 | 49.92 |
Price Performance
Historical ComparisonAbout PLTR Palantir Technologies Inc.
Palantir is an artificial intelligence, analytics, and automated decision-making company that leverages data to drive efficiency across its clients' organizations. The firm serves commercial and government clients via its Foundry and Gotham platforms, respectively. Palantir works only with entities in Western-allied nations and reserves the right not to work with anyone that is antithetical to Western values. The company was founded in 2003 and went public in 2020.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.